Pramocaine

As a commonly used local anesthetic in clinical practice, pramocaine is a benzoate ester-type local anesthetic that is neither an amide nor an ester anesthetic. Its mechanism of action is to reversibly block the sodium ion channels on the nerve cell membrane, thereby blocking the generation and conduction of nerve impulses, and it does not carry the risk of central excitation or addiction associated with cocaine-type drugs. Compared with other local anesthetics, pramocaine causes less irritation to mucous membranes, making it suitable for surface anesthesia of the skin and mucous membranes. It is commonly found in hemorrhoid ointments, antipruritic ointments, oral mucosal anesthetic preparations, etc. It can also be used for local anesthesia before endoscopic examination, covering multiple applicable groups including adults and children.

The global pramocaine market size has maintained steady growth in recent years. In 2023, the market size was approximately USD 120 million, with a compound annual growth rate maintained at around 4.3%. On the demand side, it mainly comes from the production of over-the-counter external preparations in dermatology, anorectology, stomatology and other fields. North America and Europe are the main consumer markets, accounting for 68% of the total global demand. The competitive landscape is dominated by generic drug manufacturers. After the patent of the original research product expired, the market access threshold is relatively low. China and India are the main supply origins of pramocaine API in the world, with a combined production capacity accounting for 72% of the global total. Among them, China-produced API has maintained a continuous rise in export share in recent years by virtue of its stable quality and cost advantages.

The original research enterprise of pramocaine is Hoechst Marion Roussel Inc. of the United States, and the original brand name is Pramegel. Its core compound patent expired globally in 1970. Currently, the marketed original research dosage forms are mainly 1% topical gel and 1% cream, with specifications of 15g and 30g as the main ones. The original research dosage form of this product has been included in the FDA Reference Listed Drug Catalogue, and no original research preparation has been approved for import in China so far. In terms of domestic API registration, as of now, 3 enterprises have obtained A status for their pramocaine API through CDE registration, which can be legally supplied to domestic preparation manufacturers, and another 2 enterprises have their DMF registrations under the review stage. (Data is as of November 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of pramocaine impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for the quality research and registration declaration work of API enterprises and preparation manufacturers.